PremiumBlurbsBank of America Securities Sticks to Its Buy Rating for ASML Holding NV (0QB8)19d agoASML
PremiumTipRanks NewswireNuvectis’ In-Licensed Cancer Drug Earned Breakthrough Designation in China, and It’s Not Even Their Lead Asset20d agoAZNNVS
Nuvectis’ In-Licensed Cancer Drug Earned Breakthrough Designation in China, and It’s Not Even Their Lead Asset
PremiumThe FlyAstraZeneca’s sBLA for IMFINZI plus enfortumab vedotin granted Priority Review20d agoAZN
PremiumCompany AnnouncementsHSBC Strengthens Board with Appointment of Alison Platt and Remuneration Chair Succession20d ago